BioInvent

Egetis attracts a bid and agrees to sell its priority review voucher, Lytix meets its endpoint in melanoma and Novo raises its outlook – the Nordic Pulse | 2026:45

Xbrane clears the FDA, BioInvent seeks 430 Mkr and Genmab keeps surging – the Nordic Pulse | 2026:44

Genmab clears a pivotal hurdle, AstraZeneca dominates ESMO and Bonesupport surges on Q3 – the Nordic Pulse | 2026:43– the Nordic Pulse | 2026:43

Ascendis gets the nod in Europe and Camurus wins Canada as Nordic outperformance widens – the Nordic Pulse | 2026:42

A quarter of billion-euro licences, a Novo comeback and a flat Nordic index – the State of Nordic BioPharma | 2026:Q3

BioInvent International | Investing in Life Science 2026

CSO Björn Frendéus presents BioInvent International at Investing...

AstraZeneca fires three barrels, Implantica enters the US – the Nordic Pulse | 2026:34

Novo misses, AstraZeneca holds steady, Alvotech clears FDA – the Nordic Pulse | 2026:31

Lilly calls on AlzeCure, Novo Nordisk pops a pill – the Nordic Pulse | 2026:24

Starka kliniska framsteg i fokus under BioInvents KOL-event

Under torsdagen arrangerade Bioinvent sitt andra KOL-event på...

Lundbeck breaks through, Sectra breaks records – The Nordic Pulse | 2026:23